Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022). Cell cycle control in cancer. Nature Reviews. Molecular Cell Biology, 23(1), 74–88. https://doi.org/10.1038/s41580-021-00404-3

Article  CAS  PubMed  Google Scholar 

O’Leary, B., Finn, R. S., & Turner, N. C. (2016). Treating cancer with selective CDK4/6 inhibitors. Nature Reviews. Clinical Oncology, 13(7), 417–430. https://doi.org/10.1038/nrclinonc.2016.26

Article  CAS  PubMed  Google Scholar 

Wang, Z. (2021). Regulation of cell cycle progression by growth factor-induced cell signaling. Cells, 10(12), Article 3327. https://doi.org/10.3390/cells10123327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

Article  CAS  PubMed  Google Scholar 

Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews. Drug Discovery, 14(2), 130–146. https://doi.org/10.1038/nrd4504

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lapenna, S., & Giordano, A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nature Reviews. Drug Discovery, 8(7), 547–566. https://doi.org/10.1038/nrd2907

Article  CAS  PubMed  Google Scholar 

Klocker, E. V., Egle, D., Bartsch, R., Rinnerthaler, G., & Gnant, M. (2025). Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2-early breast cancer. Drugs, 85(2), 149–169. https://doi.org/10.1007/s40265-024-02144-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021). Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences. Drugs, 81(3), 317–331. https://doi.org/10.1007/s40265-020-01461-2

Article  CAS  PubMed  Google Scholar 

Papaccio, F., García-Mico, B., Gimeno-Valiente, F., Cabeza-Segura, M., Gambardella, V., Gutiérrez-Bravo, M. F., & Castillo, J. (2023). Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Journal of Experimental & Clinical Cancer Research, 42(1), Article 8. https://doi.org/10.1186/s13046-022-02591-z

Article  CAS  Google Scholar 

Hsu, C.-L., Lui, K.-W., Chi, L.-M., Kuo, Y.-C., Chao, Y.-K., Yeh, C.-N., & Li, H.-P. (2018). Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor palbociclib as a novel candidate drug for nasopharyngeal carcinoma. Journal of Experimental & Clinical Cancer Research, 37(1), Article 233. https://doi.org/10.1186/s13046-018-0873-5

Article  CAS  Google Scholar 

Feng, M., Xu, H., Zhou, W., & Pan, Y. (2023). The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. Journal of Experimental & Clinical Cancer Research, 42(1), Article 44. https://doi.org/10.1186/s13046-023-02615-2

Article  CAS  Google Scholar 

Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A., & Dean, D. C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell, 98(6), 859–869. https://doi.org/10.1016/s0092-8674(00)81519-6

Article  CAS  PubMed  Google Scholar 

Stevaux, O., & Dyson, N. J. (2002). A revised picture of the E2F transcriptional network and RB function. Current Opinion in Cell Biology, 14(6), 684–691. https://doi.org/10.1016/s0955-0674(02)00388-5

Article  CAS  PubMed  Google Scholar 

Koch, J., Schober, S. J., Hindupur, S. V., Schöning, C., Klein, F. G., Mantwill, K., & Holm, P. S. (2022). Targeting the retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. Nature Communications, 13(1), Article 4689. https://doi.org/10.1038/s41467-022-32087-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hydbring, P., Malumbres, M., & Sicinski, P. (2016). Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nature Reviews. Molecular Cell Biology, 17(5), 280–292. https://doi.org/10.1038/nrm.2016.27

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim, S., & Kaldis, P. (2013). Cdks, cyclins and CKIs: Roles beyond cell cycle regulation. Development, 140(15), 3079–3093. https://doi.org/10.1242/dev.091744

Article  CAS  PubMed  Google Scholar 

Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016). Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. Cell Reports, 14(5), 979–990. https://doi.org/10.1016/j.celrep.2015.12.094

Article  CAS  PubMed  Google Scholar 

Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018). CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought. Cancer Cell, 34(1), 9–20. https://doi.org/10.1016/j.ccell.2018.03.023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., & Bardia, A. (2018). Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Annals of Oncology, 29(3), 640–645. https://doi.org/10.1093/annonc/mdx784

Article  CAS  PubMed  Google Scholar 

Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025). Targeting CDK4/6 in breast cancer. Experimental & Molecular Medicine, 57(2), 312–322. https://doi.org/10.1038/s12276-025-01395-3

Article  CAS  Google Scholar 

Gallanis, G. T., Sharif, G. M., Schmidt, M. O., Friedland, B. N., Battina, R., Rahhal, R., & Riegel, A. T. (2023). Stromal senescence following treatment with the CDK4/6 inhibitor palbociclib alters the lung metastatic niche and increases metastasis of drug-resistant mammary cancer cells. Cancers. https://doi.org/10.3390/cancers15061908

Article  PubMed  PubMed Central  Google Scholar 

Reid, S. E., Pantaleo, J., Bolivar, P., Bocci, M., Sjölund, J., Morsing, M., & Pietras, K. (2024). Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence. Oncogene, 43(15), 1113–1126. https://doi.org/10.1038/s41388-024-02973-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talia, M., Cirillo, F., Scordamaglia, D., Di Dio, M., Zicarelli, A., De Rosis, S., & Lappano, R. (2024). The G protein estrogen receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer. Journal of Experimental & Clinical Cancer Research, 43(1), Article 171. https://doi.org/10.1186/s13046-024-03096-7

Article  CAS  Google Scholar 

Luo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., & Keyomarsi, K. (2025). Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular Cancer, 24(1), Article 48. https://doi.org/10.1186/s12943-025-02226-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun, J., Du, R., Li, X., Liu, C., Wang, D., He, X., & Zhang, C. (2024). CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20. Cancer Letters, 588, Article 216747. https://doi.org/10.1016/j.canlet.2024.216747

Article  CAS  PubMed  Google Scholar 

Landry, B. D., Leete, T., Richards, R., Cruz-Gordillo, P., Schwartz, H. R., Honeywell, M. E., & Lee, M. J. (2018). Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells. Molecular Systems Biology, 14(8), Article e8322. https://doi.org/10.15252/msb.20188322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Micco, R., Krizhanovsky, V., Baker, D., & di d’Adda Fagagna, F. (2021). Cellular senescence in ag